The document analyzes strategies used by the alcohol industry to influence public policy on alcohol and health. It identifies four key strategies: (1) Denial of the causal link between alcohol and health harms; (2) Distortion of the scientific evidence on health risks; (3) Distraction by emphasizing other risk factors; and (4) Distinction by appealing to cultural traditions. It provides examples of these strategies used by industry groups in opposing public health warnings and policies in Ireland and at the EU level. The document concludes that the alcohol industry's influence poses a democratic problem by disregarding public health evidence in favor of corporate profits.
The document provides an update on the WHO/EU Evidence into Action Alcohol Project (EVID-ACTION). It discusses the project's focus on reducing alcohol consumption and related harms. Several upcoming activities and studies are mentioned, including workshops on brief interventions, health warnings, digital marketing, and communications. The project aims to strengthen capacity and support evidence-based alcohol policies among EU member states.
This document summarizes the key points from a presentation on alcohol labeling regulations in Ireland. It discusses the high rates of alcohol-related harm in Ireland including alcohol use disorders and deaths. It outlines Ireland's Public Health Alcohol Act of 2018 which includes provisions for minimum unit pricing and health warnings on labels. The process by which Ireland notified and finalized regulations for health warnings on labels is described, including responses from the EU and World Trade Organization. Other international developments in alcohol labeling are also mentioned.
This document summarizes Jim McCambridge's presentation on evidence regarding the alcohol industry's scientific and political strategies. It discusses:
1) The World Health Assembly (WHA) approved the Global Alcohol Action Plan (GAAP) in 2022, which aims to make alcohol a lower public health priority and limit industry interference in health policies.
2) GAAP provides a changed view of the alcohol industry as primarily a threat to health. Achieving GAAP's goals requires resources and public health engagement.
3) The WHA's 2023 "best buys" for alcohol policies include increasing alcohol taxes, restricting alcohol advertising, and limiting hours of alcohol sales. GAAP aims for 70% of countries adopting these
The document summarizes research analyzing the lobbying strategies used by the alcohol industry in France to undermine the Evin Law, which places restrictions on alcohol advertising. Through interviews with key stakeholders, the research found the industry engaged in strong lobbying that has weakened the law's enforcement since 1991. Some strategies included claiming regulations limited free speech, forming alliances with politicians, and focusing arguments on wine culture. The goal of the lobbying was to roll back limitations on advertising content and exposure to protect alcohol sales, especially to youth.
This document provides an overview of a presentation on injectable drug treatment services. The presenter discusses their experience with both poor and exemplary services. They emphasize the importance of meaningful involvement of people who use drugs in developing services. Regulations and control that are overly punitive can undermine a service and cause people to drop out. The best services work collaboratively with clients and are flexible, trusting and aim to empower rather than control. Key tips include embracing user involvement, not capping doses, not making the clinic the center of life, and never using punishments. An ideal service is like one in their town that clients want to spend time at and feel safe.
The document analyzes strategies used by the alcohol industry to influence public policy on alcohol and health. It identifies four key strategies: (1) Denial of the causal link between alcohol and health harms; (2) Distortion of the scientific evidence on health risks; (3) Distraction by emphasizing other risk factors; and (4) Distinction by appealing to cultural traditions. It provides examples of these strategies used by industry groups in opposing public health warnings and policies in Ireland and at the EU level. The document concludes that the alcohol industry's influence poses a democratic problem by disregarding public health evidence in favor of corporate profits.
The document provides an update on the WHO/EU Evidence into Action Alcohol Project (EVID-ACTION). It discusses the project's focus on reducing alcohol consumption and related harms. Several upcoming activities and studies are mentioned, including workshops on brief interventions, health warnings, digital marketing, and communications. The project aims to strengthen capacity and support evidence-based alcohol policies among EU member states.
This document summarizes the key points from a presentation on alcohol labeling regulations in Ireland. It discusses the high rates of alcohol-related harm in Ireland including alcohol use disorders and deaths. It outlines Ireland's Public Health Alcohol Act of 2018 which includes provisions for minimum unit pricing and health warnings on labels. The process by which Ireland notified and finalized regulations for health warnings on labels is described, including responses from the EU and World Trade Organization. Other international developments in alcohol labeling are also mentioned.
This document summarizes Jim McCambridge's presentation on evidence regarding the alcohol industry's scientific and political strategies. It discusses:
1) The World Health Assembly (WHA) approved the Global Alcohol Action Plan (GAAP) in 2022, which aims to make alcohol a lower public health priority and limit industry interference in health policies.
2) GAAP provides a changed view of the alcohol industry as primarily a threat to health. Achieving GAAP's goals requires resources and public health engagement.
3) The WHA's 2023 "best buys" for alcohol policies include increasing alcohol taxes, restricting alcohol advertising, and limiting hours of alcohol sales. GAAP aims for 70% of countries adopting these
The document summarizes research analyzing the lobbying strategies used by the alcohol industry in France to undermine the Evin Law, which places restrictions on alcohol advertising. Through interviews with key stakeholders, the research found the industry engaged in strong lobbying that has weakened the law's enforcement since 1991. Some strategies included claiming regulations limited free speech, forming alliances with politicians, and focusing arguments on wine culture. The goal of the lobbying was to roll back limitations on advertising content and exposure to protect alcohol sales, especially to youth.
This document provides an overview of a presentation on injectable drug treatment services. The presenter discusses their experience with both poor and exemplary services. They emphasize the importance of meaningful involvement of people who use drugs in developing services. Regulations and control that are overly punitive can undermine a service and cause people to drop out. The best services work collaboratively with clients and are flexible, trusting and aim to empower rather than control. Key tips include embracing user involvement, not capping doses, not making the clinic the center of life, and never using punishments. An ideal service is like one in their town that clients want to spend time at and feel safe.
This document discusses injectable prescribing in the UK. It shares insights and revelations from a drugs activist on their experience with injectable prescribing. Contact information is provided for the activist to discuss developing injectable services further.
Mesa_3.2. Aspectos cl”nicos en el tratamiento asistido con hero”na. La experi...PonenciesASPCAT
El documento resume la experiencia del tratamiento asistido con heroína en Suiza desde sus orígenes en 1994 hasta la actualidad. Se divide en tres etapas: Los orígenes (1994-1999) como etapa experimental, La normalización (2000-2019) como etapa de consolidación, y El cambio de enfoque (2020-2030) como etapa de diversificación. Los ensayos clínicos iniciales mostraron que el tratamiento con heroína mejora la salud y la integración social de los pacientes. Actualmente hay 1600 pacientes en tratamiento en Suiza, con mejor
Este documento presenta un resumen de los programas de tratamiento asistido con heroína en Europa y los retos para su implementación. Actualmente existen programas de tratamiento asistido con heroína en 5 países de la UE y 7 países europeos. Estos programas han demostrado reducir el uso de heroína y otras drogas ilegales, así como la delincuencia. Sin embargo, su implementación plantea retos como traducir la evidencia a la práctica clínica, obtener apoyo regulatorio y financiamiento, y superar los estigmas asociados con el trat
Tractament amb heroïna: una alternativa. Antecedents, situació actual i reptes de futur. ASpectos legales y viabilidad en la implementación de programas de tratamiento con heroína en España.
1. Se realizó un ensayo clínico en Cataluña para comparar la eficacia de la diacetilmorfina oral, la morfina oral y la metadona oral en el tratamiento de usuarios dependientes de heroína.
2. Los resultados mostraron que el 90% de los pacientes se mantuvieron en el estudio y que todos los tratamientos proporcionaron un alivio similar de los síntomas de abstinencia.
3. Los pacientes, enfermeras y médicos no pudieron distinguir cuál opioide estaban tomando los pacientes, lo
Este documento discute la satisfacción de pacientes en tratamiento con metadona. Presenta una escala para medir la satisfacción del paciente con la metadona y los resultados de estudios que muestran una satisfacción media de los pacientes y factores asociados con una menor satisfacción como un mayor consumo reciente de heroína. El documento concluye que la metadona es un tratamiento eficaz pero no ideal y que se necesitan más opciones de agonistas opioides.
Tractament amb heroïna: una alternativa. Antecedents, situació actual i reptes de futur > L'experiència del programa de prescripció d'heroïna a Andalusia.
This document provides an overview of a presentation on injectable drug treatment services. The presenter discusses their experience with both poor and exemplary services. They emphasize the importance of meaningful involvement of people who use drugs in developing services. Regulations and control that are overly punitive can undermine a service and cause people to drop out. The best services work collaboratively with clients and are flexible, trusting and aim to empower rather than control. Key tips include embracing user involvement, not capping doses, not making the clinic the center of life, and never using punishments. An ideal service is like one in their town that clients want to spend time at and feel safe.
This document discusses injectable prescribing in the UK. It shares insights and revelations from a drugs activist on their experience with injectable prescribing. Contact information is provided for the activist to discuss developing injectable services further.
La dependencia de opiáceos es un trastorno crónico recurrente que requiere un tratamiento a largo plazo. La administración controlada de un fármaco opioide, durante un período de tiempo prolongado, se presenta como el tratamiento de elección en el caso de pacientes dependientes de opiáceos. La introducción de los tratamientos con metadona fue determinante para facilitar el acceso a la red de personas que no llegaban a tratamiento.
The document summarizes the objectives and activities of the FAR SEAS project, which aims to promote strategies to prevent fetal alcohol syndrome and fetal alcohol spectrum disorder across EU member states. Key activities include:
- Identifying best practices in Europe for preventing alcohol-exposed pregnancies
- Developing guidelines to reduce alcohol consumption among women of child-bearing age
- Creating a training package for professionals on brief interventions
- Conducting a pilot study in Poland to test implementation of prevention strategies at the regional level
- Hosting workshops and a dissemination event to facilitate knowledge sharing on alcohol policy topics between member states.
This document discusses injectable prescribing in the UK. It shares insights and revelations from a drugs activist on their experience with injectable prescribing. Contact information is provided for the activist to discuss developing injectable services further.
Mesa_3.2. Aspectos cl”nicos en el tratamiento asistido con hero”na. La experi...PonenciesASPCAT
El documento resume la experiencia del tratamiento asistido con heroína en Suiza desde sus orígenes en 1994 hasta la actualidad. Se divide en tres etapas: Los orígenes (1994-1999) como etapa experimental, La normalización (2000-2019) como etapa de consolidación, y El cambio de enfoque (2020-2030) como etapa de diversificación. Los ensayos clínicos iniciales mostraron que el tratamiento con heroína mejora la salud y la integración social de los pacientes. Actualmente hay 1600 pacientes en tratamiento en Suiza, con mejor
Este documento presenta un resumen de los programas de tratamiento asistido con heroína en Europa y los retos para su implementación. Actualmente existen programas de tratamiento asistido con heroína en 5 países de la UE y 7 países europeos. Estos programas han demostrado reducir el uso de heroína y otras drogas ilegales, así como la delincuencia. Sin embargo, su implementación plantea retos como traducir la evidencia a la práctica clínica, obtener apoyo regulatorio y financiamiento, y superar los estigmas asociados con el trat
Tractament amb heroïna: una alternativa. Antecedents, situació actual i reptes de futur. ASpectos legales y viabilidad en la implementación de programas de tratamiento con heroína en España.
1. Se realizó un ensayo clínico en Cataluña para comparar la eficacia de la diacetilmorfina oral, la morfina oral y la metadona oral en el tratamiento de usuarios dependientes de heroína.
2. Los resultados mostraron que el 90% de los pacientes se mantuvieron en el estudio y que todos los tratamientos proporcionaron un alivio similar de los síntomas de abstinencia.
3. Los pacientes, enfermeras y médicos no pudieron distinguir cuál opioide estaban tomando los pacientes, lo
Este documento discute la satisfacción de pacientes en tratamiento con metadona. Presenta una escala para medir la satisfacción del paciente con la metadona y los resultados de estudios que muestran una satisfacción media de los pacientes y factores asociados con una menor satisfacción como un mayor consumo reciente de heroína. El documento concluye que la metadona es un tratamiento eficaz pero no ideal y que se necesitan más opciones de agonistas opioides.
Tractament amb heroïna: una alternativa. Antecedents, situació actual i reptes de futur > L'experiència del programa de prescripció d'heroïna a Andalusia.
This document provides an overview of a presentation on injectable drug treatment services. The presenter discusses their experience with both poor and exemplary services. They emphasize the importance of meaningful involvement of people who use drugs in developing services. Regulations and control that are overly punitive can undermine a service and cause people to drop out. The best services work collaboratively with clients and are flexible, trusting and aim to empower rather than control. Key tips include embracing user involvement, not capping doses, not making the clinic the center of life, and never using punishments. An ideal service is like one in their town that clients want to spend time at and feel safe.
This document discusses injectable prescribing in the UK. It shares insights and revelations from a drugs activist on their experience with injectable prescribing. Contact information is provided for the activist to discuss developing injectable services further.
La dependencia de opiáceos es un trastorno crónico recurrente que requiere un tratamiento a largo plazo. La administración controlada de un fármaco opioide, durante un período de tiempo prolongado, se presenta como el tratamiento de elección en el caso de pacientes dependientes de opiáceos. La introducción de los tratamientos con metadona fue determinante para facilitar el acceso a la red de personas que no llegaban a tratamiento.
The document summarizes the objectives and activities of the FAR SEAS project, which aims to promote strategies to prevent fetal alcohol syndrome and fetal alcohol spectrum disorder across EU member states. Key activities include:
- Identifying best practices in Europe for preventing alcohol-exposed pregnancies
- Developing guidelines to reduce alcohol consumption among women of child-bearing age
- Creating a training package for professionals on brief interventions
- Conducting a pilot study in Poland to test implementation of prevention strategies at the regional level
- Hosting workshops and a dissemination event to facilitate knowledge sharing on alcohol policy topics between member states.
1. UBA adults >15
Via 2: Prevencióindicada
Derivacióintoxicació
etílicaper seguimentAP
SEM o Urgències->
Informe altaUBA
“Cribratge oportunista” Infermeria
En el darreranyquants dies has begutmés d’uns glops de cervesa,
vi o d’alguna beguda quecontingui alcohol? Número dedies
Via 1: Prevencióuniversal
+ INFO
cribratge
Secció 5
guia
No beu
Reforç conducta
Exploració del context
Patrons de consum
Problemes derivats
Context familiar
Consum altres drogues
Possibleinterconsulta TSS
+ INFO
intervenció
Secció 7-9
guia
Risc baix
Intervenció breu
Intervencióbreuo
entrevistamotivacional
o
Interconsulta/derivacióCSMIJ
Seguiment (1 any)